tissue-engineered acellular vascular graft

Class

tissue-engineered acellular vascular graft (bioengineered regenerative-medicine device, not a receptor/enzyme-targeted drug)

Pathway

Human vascular smooth muscle cells from FDA-registered donors are expanded and seeded onto a biodegradable polyglycolic acid mesh scaffold in a bioreactor, then decellularized; implanted as an off-the-shelf vascular conduit that is gradually repopulated by the host's own cells in vivo (structural/regenerative mechanism, no molecular target)

Notes

original target text: tissue-engineered acellular vascular graft (bioengineered regenerative-medicine device, not a receptor/enzyme-targeted drug)

This entry describes a bioengineered blood-vessel substitute rather than a drug acting on a molecular target. Some medical conditions, such as kidney failure requiring dialysis access, traumatic vascular injury, or blocked arteries in the legs, require a replacement blood vessel when a patient's own vessels are unsuitable or unavailable. Traditional options include the patient's own vein, a vessel from a donor, or a synthetic plastic tube; each has drawbacks, including limited supply, risk of infection, clotting, or immune rejection. A tissue-engineered acellular vascular graft addresses this by growing vascular smooth muscle cells from screened donors onto a biodegradable mesh scaffold under conditions that encourage the cells to deposit their own structural proteins, then removing the cells themselves before implantation. What remains is a tube built mostly of the body's own structural materials rather than living donor cells, which lowers the chance that a recipient's immune system will recognize and reject it. Once implanted, the recipient's own vascular cells gradually migrate into and repopulate the graft, converting it over time into a living, self-maintaining vessel. This approach broadly matters wherever a durable, readily available, low-immunogenicity conduit is needed to restore blood flow.